Clinical Experience of Using LHRH antagonist Degarelix in advanced prostate cancer- Assessment of Side effects, tolerance and efficacy
Total Number- 36 patients
Median Age
Median BMI
Mean baselineTestosterone (8 pts)- 254 ( -
Stage
Locally advanced- 9
Metastatic- 27
Median PSA
Locally advanced- 21.2 (11- 38.5)
Metastatic- 47 (28-1340)
Gleason score 6-7 8-10
Methods:
Data about all patients who received injection degarelix as treatment for prostate cancer in routine clinical practice was collected prospectively and analysed retrospectively. Patients with atleast 3 months of follow up were included in study. Decision of treating patients with injection degarelix was taken by treating physician and patients, after explaining all the options
Total Number- 36 patients
Median Age
Median BMI
Mean baselineTestosterone (8 pts)- 254 ( -
Stage
Locally advanced- 9
Metastatic- 27
Median PSA
Locally advanced- 21.2 (11- 38.5)
Metastatic- 47 (28-1340)
Gleason score 6-7 8-10
Methods:
Data about all patients who received injection degarelix as treatment for prostate cancer in routine clinical practice was collected prospectively and analysed retrospectively. Patients with atleast 3 months of follow up were included in study. Decision of treating patients with injection degarelix was taken by treating physician and patients, after explaining all the options